Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant

<p><strong>Background</strong></p> Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2...

Full description

Bibliographic Details
Main Authors:	Madhi, SA, Baillie, V, Cutland, CL, Voysey, M, Koen, AL, Fairlie, L, Padayachee, SD, Dheda, K, Barnabas, SL, Bhorat, QE, Briner, C, Kwatra, G, Ahmed, K, Aley, P, Bhikha, S, Bhiman, JN, Bhorat, AE, du Plessis, J, Esmail, A, Groenewald, M, Horne, E, Hwa, S-H, Jose, A, Lambe, T, Laubscher, M, Malahleha, M, Masenya, M, Masilela, M, McKenzie, S, Molapo, K, Moultrie, A, Oelofse, S, Patel, F, Pillay, S, Rhead, S, Rodel, H, Rossouw, L, Taoushanis, C, Tegally, H, Thombrayil, A, van Eck, S, Wibmer, CK, Durham, NM, Kelly, EJ, Villafana, TL, Gilbert, S, Pollard, AJ, de Oliveira, T, Moore, PL, Sigal, A, Izu, A
Other Authors:	NGS-SA Group
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2021

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant

Similar Items